This site is intended for healthcare professionals

Horizon Therapeutics plc initiates randomized controlled clinical trial evaluating Tepezza for the treatment of chronic (inactive) thyroid eye disease.

Read time: 1 mins
Last updated:9th Sep 2021
Published:9th Sep 2021
Horizon Therapeutics plc has announced that the first patient has been enrolled in a Phase IV clinical trial evaluating the efficacy and safety of Tepezza for the treatment of chronic (inactive) TED.
Condition: Thyroid Eye Disease
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest